ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: A multicenter fully nurse-coordinated intensive intervention program

Giorgia Paoli, Maria Francesca Notarangelo, Maria Mattioli, Rachele La Sala, Chiara Foà, Emilia Solinas, Sara Fusco, Cristian Fava, Caterina Caminiti, Giovanna Artioli, Giovanna Pelà, Elisabetta Dall'Aglio, Antonio Manari, Stefano Tondi, Antonio Rizzo, Gaia Trapolin, Giampiero Patrizi, Stefano Cappelli, Giovanni Quinto Villani, Massimo PiepoliGianni Zobbi, Elisa Nicosia, Diego Ardissino

Research output: Contribution to journalArticlepeer-review

Abstract

The main objective of cardiovascular disease prevention is to reduce morbidity and mortality by promoting a healthy lifestyle, reducing risk factors, and improving adherence to medications. Secondary prevention after an acute coronary syndrome has proved to be effective in reducing new cardiovascular events, but its limited use in everyday clinical practice suggests that there is considerable room for improvement. The short-term results of evidence-based studies of nurse-coordinated secondary prevention programs have been positive, but there is a lack of long-term outcome data. The Alliance for the Secondary Prevention of Cardiovascular Disease in the Emilia-Romagna region (ALLEPRE) is a multicenter, randomized, controlled trial designed to compare the effects of a structured nurse-coordinated intensive intervention on long-term outcomes and risk profiles after an acute coronary syndrome with those of the standard of care. All of the patients randomized to the intervention group take part in 9 one-to-one sessions with an experienced nurse from the participating centers with the aim at promoting healthy lifestyles, reducing risk factors, and increasing adherence to medication over a mean period of 5 years. The primary clinical end point is the reduction in the risk of the 5-year occurrence of major adverse events (a composite of cardiovascular mortality, nonfatal reinfarction, and nonfatal stroke). The primary surrogate end point is the achievement of prespecified targets relating to classical risk factors, lifestyle modifications, and adherence to pharmacological therapy after 2 years of follow-up.

Original languageEnglish
Pages (from-to)12-16
Number of pages5
JournalAmerican Heart Journal
Volume203
DOIs
Publication statusPublished - Sept 1 2018
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: A multicenter fully nurse-coordinated intensive intervention program'. Together they form a unique fingerprint.

Cite this